Safety and Cost of Low-Molecular-Weight Heparin as Bridging Anticoagulant Therapy in Subacute Cerebral Ischemia | Zendy

Mary Kalafut | Zendy; Rohina Gandhi | Zendy; Chelsea S. Kidwell | Zendy; Jeffrey L. Saver | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Cost of Low-Molecular-Weight Heparin as Bridging Anticoagulant Therapy in Subacute Cerebral Ischemia

Author(s) -

Mary Kalafut,

Rohina Gandhi,

Chelsea S. Kidwell,

Jeffrey L. Saver

Publication year - 2000

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/01.str.31.11.2563

Subject(s) - medicine , heparin , bridging (networking) , anticoagulant therapy , low molecular weight heparin , ischemia , anesthesia , intensive care medicine , cardiology , computer network , computer science

Anticoagulation with intravenous unfractionated heparin (IVUH) while awaiting therapeutic oral anticoagulant levels is a common practice in patients with acute and subacute cerebral ischemia. A promising alternative strategy is to use bridging subcutaneous low-molecular-weight heparin (LMWH), which may have a favorable risk-benefit profile compared with IVUH and may permit earlier discharge with completion of transition to warfarin therapy as an outpatient.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research